Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G/A

EyePoint,

EYPTNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Oct 7, 2026Accepted Oct 7, 2026, 7:22 AM EDTFiling CIK 1314102Accession 0001623632-26-001550
Share

Structured filing — SCHEDULE 13G/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
EyePoint
Company CIK
0001314102
Street
480 Pleasant Street, Suite C400
City
Watertown
State / country code
MA
Postal code
02472

Statement details

Amendment number
2
Security class
COMMON STOCK
Event date
09/30/2026
Rule designation
Rule 13d-1(b)

Reporting person 1

Name
Federated Hermes, Inc.
Citizenship / organization
PA
Reporting person type
HC
Aggregate amount owned
6,934,414.00
Percent of class
8.04
Sole voting power
6,934,414.00
Shared voting power
0.00
Sole dispositive power
6,934,414.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N

Reporting person 2

Name
Voting Shares Irrevocable Trust
Citizenship / organization
PA
Reporting person type
OO
Aggregate amount owned
6,934,414.00
Percent of class
8.04
Sole voting power
6,934,414.00
Shared voting power
0.00
Sole dispositive power
6,934,414.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N
Comments
In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.

Reporting person 3

Name
Thomas R. Donahue
Citizenship / organization
X1
Reporting person type
IN
Aggregate amount owned
6,934,414.00
Percent of class
8.04
Sole voting power
0.00
Shared voting power
6,934,414.00
Sole dispositive power
0.00
Shared dispositive power
6,934,414.00
Aggregate excludes certain shares
N
Comments
In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.

Reporting person 4

Name
Ann C. Donahue
Citizenship / organization
X1
Reporting person type
IN
Aggregate amount owned
6,934,414.00
Percent of class
8.04
Sole voting power
0.00
Shared voting power
6,934,414.00
Sole dispositive power
0.00
Shared dispositive power
6,934,414.00
Aggregate excludes certain shares
N
Comments
In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.

Reporting person 5

Name
J. Christopher Donahue
Citizenship / organization
X1
Reporting person type
IN
Aggregate amount owned
6,934,414.00
Percent of class
8.04
Sole voting power
0.00
Shared voting power
6,934,414.00
Sole dispositive power
0.00
Shared dispositive power
6,934,414.00
Aggregate excludes certain shares
N
Comments
In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.

Item 1

Issuer

EyePoint

Principal executive office address

480 Pleasant Street, Suite C400, Watertown, MA 02472

Item 2

Citizenship

Pennsylvania

Filing person

Federated Hermes, Inc.

Principal business or residence address

1001 Liberty Avenue, Pittsburgh, PA 15222-3779

Item 3

Not applicable indication

N

Type of filing person

HC

Item 4

Percent of class

See response to Item 11 on each cover page.

Amount beneficially owned

See response to Item 9 on each cover page.

Sole voting power

See response to Item 5 on each cover page.

Shared voting power

See response to Item 6 on each cover page.

Sole dispositive power

See response to Item 7 on each cover page.

Shared dispositive power

See response to Item 8 on each cover page.

Item 5

Not applicable indication

Y

Item 6

Not applicable indication

Y

Item 7

Not applicable indication

N

Subsidiaries

See Exhibit "1" Attached

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Signature comments

SEE EXHIBITS 2 AND 3 ATTACHED Exhibit Information EXHIBIT 1 ITEM 3 CLASSIFICATION OF REPORTING PERSONS EXHIBIT 2 AGREEMENT FOR JOINT FILING OF SCHEDULE 13G EXHIBIT 3 POWER OF ATTORNEY

Signature 1

Reporting person
Federated Hermes, Inc.
Signed
/s/J. Christopher Donahue
Title
J. Christopher Donahue, as President of Federated Hermes, Inc.
Date
10/07/2026

Signature 2

Reporting person
Voting Shares Irrevocable Trust
Signed
/s/Thomas R. Donahue · /s/Ann C. Donahue · /s/J. Christopher Donahue
Title
Thomas R. Donahue, as Trustee of Voting Shares Irrevocable Trust · Ann C. Donahue, as Trustee of Voting Shares Irrevocable Trust · J. Christopher Donahue, as Trustee of Voting Shares Irrevocable Trust
Date
10/07/2026 · 10/07/2026 · 10/07/2026

Signature 3

Reporting person
Thomas R. Donahue
Signed
/s/Thomas R. Donahue
Title
Thomas R. Donahue
Date
10/07/2026

Signature 4

Reporting person
Ann C. Donahue
Signed
/s/Ann C. Donahue
Title
Ann C. Donahue
Date
10/07/2026

Signature 5

Reporting person
J. Christopher Donahue
Signed
/s/J. Christopher Donahue
Title
J. Christopher Donahue
Date
10/07/2026

Filed exhibits

Company context

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with EyePoint’s proprietary bioerodible Durasert E™ sustained-delivery technology. DURAVYU is currently being evaluated in Phase 3 pivotal trials for diabetic macular edema (DME).

Current securities

Recent company filings

  1. SCHEDULE 13G - filed by TANG CAPITAL MANAGEMENT LLC regarding EyePoint, Inc.Oct 27, 2026
  2. Results of Operations and Financial Condition · Costs Associated with Exit or Disposal Activities · Other EventsOct 19, 2026
  3. Other EventsOct 19, 2026
  4. Other EventsSep 10, 2026
  5. 4 filingAug 18, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.